Pyoderma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MalaCards based summary: Pyoderma is related to crohn's disease and neutrophilic dermatosis, acute febrile, and has symptoms including pruritus, exanthema and pustular rash. An important gene associated with Pyoderma is PSTPIP1 (Proline-Serine-Threonine Phosphatase Interacting Protein 1), and among its related pathways/superpathways are MIF Mediated Glucocorticoid Regulation and Akt Signaling. The drugs Anti-Inflammatory Agents and Endothelial Growth Factors have been mentioned in the context of this disorder. Affiliated tissues include skin, neutrophil and breast, and related phenotypes are immune system and neoplasm

Wikipedia: ⁷⁵ Pyoderma means any skin disease that is pyogenic (has pus). These include superficial bacterial... more...

Sources

Related Diseases for Pyoderma

Diseases related to Pyoderma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 893)

#	Related Disease	Score	Top Affiliating Genes
1	crohn's disease	31.9	TNF NOD2 CXCL8 CCR6
2	neutrophilic dermatosis, acute febrile	31.9	TNF PSTPIP1 MEFV CXCL8 CSF3
3	inflammatory bowel disease 1	31.6	TNF NOD2 CCR6
4	pyoderma gangrenosum	31.5	TNF PSTPIP1 NOD2 MMP9 MMP26 MMP10
5	ulcerative colitis	31.4	TNF NOD2 IL1R1 CXCL8 CCR6
6	hidradenitis	31.3	TNF PSTPIP1 NOD2 MEFV
7	hidradenitis suppurativa	31.3	TNF PSTPIP1 NOD2 MEFV
8	acne	31.2	TNF PSTPIP1 MMP1 MEFV CXCL8
9	colitis	31.2	TNF NOD2 IL1R1 CXCL8 CCR6
10	vasculitis	31.0	TNF MEFV ITGB2 IFNA2 CXCL8 APOH
11	erythema nodosum	31.0	TNF NOD2 CXCL8
12	dermatitis	31.0	TNF NOD2 CXCL8 CCR6
13	fasciitis	30.9	TNF MYOM2 MMP1 CXCL8
14	necrotizing fasciitis	30.9	TNF MYOM2 F3 CXCL8
15	myelodysplastic syndrome	30.9	TNF IFNA2 CXCL8 CSF3 CCR6
16	myelofibrosis	30.8	TNF IFNA2 CXCL8 CSF3
17	hypersensitivity vasculitis	30.8	TNF MEFV CCR6
18	chronic recurrent multifocal osteomyelitis	30.8	TNF PSTPIP1 NOD2 MEFV
19	skin disease	30.7	TNF NOD2 MMP9 MMP1 MEFV ITGB2
20	erythema elevatum diutinum	30.7	PSTPIP1 CXCL8
21	inflammatory bowel disease	30.7	TNF PSTPIP1 NOD2 MMP9 MMP1 ITGB2
22	spondyloarthropathy 1	30.7	TNF NOD2 IL1R1 CCR6
23	polyarteritis nodosa	30.7	TNF MEFV ITGB2 IFNA2 APOH
24	agammaglobulinemia, x-linked	30.7	PLCG2 CCR6 BTK
25	polycythemia vera	30.7	TNF IFNA2 F3 CSF3
26	osteomyelitis	30.7	TNF NOD2 MMP1 MEFV CXCL8 CSF3
27	ecthyma	30.6	CSF3 BTK
28	fungal infectious disease	30.6	TNF CXCL8 CSF3 CCR6
29	diarrhea	30.6	TNF NOD2 IFNA2 CXCL8 CSF3
30	rosacea	30.6	TNF MMP9 CXCL8
31	panniculitis	30.6	CSF3 CCR6 BTK
32	purpura	30.5	TNF F3 CXCL8 APOH
33	autoimmune disease	30.5	TNF MMP9 F3 CCR6 APOH
34	antiphospholipid syndrome	30.5	TNF F3 APOH
35	diverticulitis	30.5	TNF MMP9 CCR6
36	psoriasis	30.5	TNF NOD2 ITGB2 IL1R1 CXCL8 CCR6
37	pouchitis	30.5	TNF NOD2
38	cholangitis	30.5	TNF NOD2 F3 CXCL8
39	exanthem	30.5	TNF F3 CXCL8 CSF3 CCR6
40	leukemia, acute myeloid	30.5	TNF MMP9 CXCL8 CSF3 CCR6 BTK
41	keratitis, hereditary	30.5	TNF MMP9 CXCL8 CCR6
42	leukocyte adhesion deficiency, type i	30.5	ITGB2 CSF3 CCR6
43	spondylitis	30.5	TNF NOD2 CCR6
44	neutropenia	30.4	TNF IFNA2 CXCL8 CSF3
45	aortitis	30.4	TNF CSF3 CCR6
46	scleritis	30.4	TNF MMP9 ITGB2 CCR6
47	deficiency anemia	30.4	TNF IFNA2 F3 CSF3 CCR6
48	pharyngitis	30.4	TNF MYOM2 MEFV CXCL8 CCR6
49	myeloma, multiple	30.4	MYOM2 ITGB2 IFNA2 CSF3 CCR6
50	brucellosis	30.4	TNF MEFV CXCL8

Comorbidity relations with Pyoderma via Phenotypic Disease Network (PDN):

Acute Cystitis	Decubitus Ulcer
Deficiency Anemia	Heart Disease
Peripheral Vascular Disease

Graphical network of the top 20 diseases related to Pyoderma:

Sources

Symptoms & Phenotypes for Pyoderma

UMLS symptoms related to Pyoderma:

pruritus; exanthema; pustular rash

GenomeRNAi Phenotypes related to Pyoderma according to GeneCards Suite gene sharing:

²⁵

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	no effect	GR00402-S-1	10.2	APOH BTK C7 CCR6 CSF3 CXCL8
2	no effect	GR00402-S-2	10.2	APOH BTK C7 CCR6 CSF3 F3

MGI Mouse Phenotypes related to Pyoderma:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	immune system	MP:0005387	10.03	BTK CCR6 CSF3 F3 IFNA2 IL1R1
2	neoplasm	MP:0002006	9.8	BTK F3 IL1R1 MMP1 MMP9 PLCG2
3	hematopoietic system	MP:0005397	9.77	BTK CCR6 CSF3 F3 IFNA2 IL1R1
4	integument	MP:0010771	9.32	BTK CSF3 F3 IL1R1 ITGB2 MEFV

Sources

Drugs & Therapeutics for Pyoderma

Drugs for Pyoderma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 18)

#

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

1

Anti-Inflammatory Agents

Phase 4

2

Endothelial Growth Factors

Phase 4

3

Mitogens

Phase 4

4

Adalimumab

Approved, Experimental

Phase 3

331731-18-1

5

Antirheumatic Agents

Phase 3

6

Pharmaceutical Solutions

Phase 3

7

Ixekizumab

Approved, Investigational

Phase 2

1143503-69-8

8

Prednisone

Approved, Vet_approved

Phase 2

53-03-2

5865

Synonyms:

1,2-Dehydrocortisone

1,4-Pregnadiene-17a,21-diol-3,11,20-trione

1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione

1,4-Pregnadiene-17α,21-diol-3,11,20-trione

17,21-Dihydroxypregna-1,4-diene-3,11,20-trione

Acis brand OF prednisone

Acsis, prednison

Adasone

Ancortone

Apo-prednisone

Apotex brand OF prednisone

Aventis brand OF prednisone

Betapar

Bicortone

Cartancyl

Colisone

Cortan

Cortancyl

Cortidelt

Cotone

Cutason

Dacorten

Dacortin

Decortancyl

Decortin

Decortisyl

Dehydrocortisone

Dekortin

Delcortin

Dellacort

Dellacort A

Delta Cortelan

Delta E

Delta-cortelan

Deltacortene

delta-Cortisone

Deltacortisone

Deltacortone

Delta-cortone

DELTA-DOME

Deltasone

Deltison

Deltisona

Deltisone

Deltra

Diadreson

Di-Adreson

Diba brand OF prednisone

Econosone

Encorton

Encortone

Enkortolon

Enkorton

Fawns and mcallan brand OF prednisone

FERNISONE

Ferring brand OF prednisone

Fiasone

GALENpharma brand OF prednisone

Halsey drug brand OF prednisone

Hexal brand OF prednisone

Hoechst brand OF prednisone

Hostacortin

ICN brand OF prednisone

Incocortyl

In-Sone

Juvason

Kortancyl

Lichtenstein brand OF prednisone

Liquid pred

Lisacort

LODOTRA

Lodotra®|Sterapred®

Me-Korti

Merck brand OF prednisone

Merz brand OF prednisone

Metacortandracin

Meticorten

Mibe brand OF prednisone

Nisona

Nizon

Novoprednisone

NSC-10023

Nurison

Orasone

Origen Prednisone

Panafcort

Panasol

PARACORT

Parmenison

Pehacort

Pharmacia brand OF prednisone

PRD

Precort

Predeltin

PREDN

Predni tablinen

PREDNICEN-M

Prednicorm

Prednicort

Prednicot

Prednidib

Prednilonga

Predniment

Prednison

Prednison acsis

Prednison galen

Prednison hexal

Prednisona

Prednisona [INN-Spanish]

Prednisone

PREDNISONE INTENSOL

PREDNISONE TABLETS

Prednisonum

Prednisonum [INN-Latin]

Prednitone

Prednizon

Prednovister

Presone

Pronison

Pronisone

RAYOS

Rectodelt

Retrocortine

Schering-plough brand OF prednisone

Seatrace brand OF prednisone

SERVISONE

Solvay brand OF prednisone

Sone

Sterapred

Supercortil

Trommsdorff brand OF prednisone

Ultracorten

Ultracortene

Winpred

Wojtab

Zenadrid

9

Vilobelimab

Investigational

Phase 2

2250440-41-4

10

Dermatologic Agents

Phase 2

11

Complement System Proteins

Phase 2

12

Immunosuppressive Agents

Phase 2

13

Infliximab

Approved

170277-31-3

14

D-Tyrosine

Approved, Experimental, Investigational, Nutraceutical

133585-56-5, 60-18-4, 556-02-5

1153 6057

Synonyms:

(-)-a-Amino-p-hydroxyhydrocinnamate

(-)-a-Amino-p-hydroxyhydrocinnamic acid

(-)-alpha-Amino-p-hydroxyhydrocinnamate

(-)-alpha-Amino-p-hydroxyhydrocinnamic acid

(-)-Α-amino-p-hydroxyhydrocinnamate

(−)-α-amino-p-hydroxyhydrocinnamic acid

(-)-Α-amino-p-hydroxyhydrocinnamic acid

(2S)-2-Amino-3-(4-hydroxyphenyl)propanoate

(2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid

(2S)-2-AMINO-3-(4-HYDROXYPHENYL)PROPIONIC ACID

(2S)-2-AZANYL-3-(4-HYDROXYPHENYL)PROPANOIC ACID

(R)-2-Amino-3-(p-hydroxyphenyl)propionic acid

(R)-3-(p-Hydroxyphenyl)alanine

(S)-(-)-Tyrosine

(S)-2-Amino-3-(p-hydroxyphenyl)propionate

(S)-2-Amino-3-(p-hydroxyphenyl)propionic acid

(S)-3-(p-Hydroxyphenyl)alanine

(S)-a-Amino-4-hydroxybenzenepropanoate

(S)-a-Amino-4-hydroxy-benzenepropanoate

(S)-a-Amino-4-hydroxybenzenepropanoic acid

(S)-a-Amino-4-hydroxy-benzenepropanoic acid

(S)-alpha-Amino-4-hydroxybenzenepropanoate

(S)-alpha-Amino-4-hydroxy-benzenepropanoate

(S)-alpha-amino-4-Hydroxybenzenepropanoic acid

(S)-alpha-Amino-4-hydroxy-benzenepropanoic acid

(S)-Tyrosine

(S)-Α-amino-4-hydroxybenzenepropanoate

(S)-α-amino-4-hydroxybenzenepropanoic acid

2-Amino-3-(4-hydroxyphen yl)-2-amino-3-(4-hydroxyphenyl)-propanoate

2-Amino-3-(4-hydroxyphen yl)-2-amino-3-(4-hydroxyphenyl)-propanoic acid

2-Amino-3-(4-hydroxyphenyl)propanoate

2-Amino-3-(4-hydroxyphenyl)propanoic acid

2-Amino-3-(p-hydroxyphenyl)propionate

2-Amino-3-(p-hydroxyphenyl)propionic acid

3-(4-Hydroxyphenyl)-L-alanine

3-(p-Hydroxyphenyl)alanine

4-hydroxy-L-phenylalanine

6-Hydroxysandoricin

Benzenepropanoate

Benzenepropanoic acid

D-Tyr

D-Tyrosin

FEMA NO. 3736

L Tyrosine

LEVODOPA IMPURITY, L-TYROSINE-

LEVODOPA RELATED COMPOUND L-TYROSINE

L-p-Tyrosine

L-Tyrosin

L-tyrosine

Methyl 2-[5,11-bis(acetyloxy)-13-(furan-3-yl)-16-hydroxy-6,6,8,12-tetramethyl-17-methylidene-15-oxo-2,14-dioxatetracyclo[7.7.1.0¹,¹².0³,⁸]heptadecan-7-yl]-2-hydroxyacetic acid

NSC-82624

Para tyrosine

Para-tyrosine

p-Tyrosine

Tirosina

Tyr

Tyrosin

Tyrosine

Tyrosine, L isomer

Tyrosine, L-isomer

Tyrosinum

Y

15

Gastrointestinal Agents

16

Vaccines

17

Immunoglobulins, Intravenous

Early Phase 1

18

Antineoplastic Agents, Immunological

Early Phase 1

Interventional clinical trials:

(show all 30)

#	Name	Status	NCT ID	Phase	Drugs
1	A Novel Therapeutic Treatment of Pyoderma Gangrenosum	Recruiting	NCT05120726	Phase 4
2	Sisomicin Cream Vs Nadifloxacin Cream in Primary Pyodermas	Withdrawn	NCT00202891	Phase 4	sisomicin
3	A Phase 3 Multicenter, Open-Label, Single Arm Study of the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Subjects in Japan	Completed	NCT03311464	Phase 3	adalimumab
4	Opened, Multicenter, Randomized, in Parallel Groups Comparative Study to Assess Efficacy and Safety of Dioxidin®, Solution for Topical and External Application 0.025% (Valenta Farm, Russia) and Miramistin®, Solution for Topical Application 0.01% (Infamed K LLC, Russia) in Treatment of Superficial Pyoderma	Recruiting	NCT05561816	Phase 3	Hydroxymethylquinoxalindioxyde;Benzyl-dimethyl-[3-(tetradecanoylamino)propyl]azanium
5	Hyperbaric Oxygen Therapy for Pyoderma Gangrenosum As a New Treatment Strategy	Not yet recruiting	NCT05343754	Phase 3	Hyperbaric oxygen
6	A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum	Terminated	NCT02315417	Phase 3	gevokizumab;Placebo;gevokizumab open-label
7	A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum	Terminated	NCT02326740	Phase 3	gevokizumab;Placebo;gevokizumab open-label
8	A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Patients With Pyoderma Gangrenosum	Terminated	NCT02318914	Phase 3	gevokizumab
9	Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma Gangrenosum	Unknown status	NCT02733094	Phase 1, Phase 2	Secukinumab
10	An Open-label, Proof of Concept Study of Gevokizumab in the Treatment of the Acute, Inflammatory Phase of Pyoderma Gangrenosum	Completed	NCT01882504	Phase 2	gevokizumab
11	A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum	Completed	NCT01965613	Phase 2
12	An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum	Completed	NCT03137160	Phase 2
13	Open Label Exploratory Phase 2a Trial to Investigate the Safety and Efficacy of IFX-1 in Treating Subjects With Pyoderma Gangrenosum (Optima)	Completed	NCT03971643	Phase 2	IFX-1
14	A Phase II Multi Center Open Label Pilot Study To Assess a Potential Effect of an Anti-Il-1-Beta Antagonist in the Treatment of Pyoderma Gangrenosum	Completed	NCT01302795	Phase 2	Canakinumab
15	Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)	Recruiting	NCT04901325	Phase 2	Baricitinib
16	A Phase 2a, Open-label, Proof of Concept Study to Determine the Efficacy and Safety of Etrasimod (APD334) in Patients With Pyoderma Gangrenosum	Terminated	NCT03072953	Phase 2	APD334
17	The Efficacy and Safety of Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum	Withdrawn	NCT04274166	Phase 2	secukinumab 150 mg (2 injections per dose
18	A Multi-Center, Open Label Pilot Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum (HUM 04-37)	Withdrawn	NCT00690846	Phase 2	adalimumab
19	Multi Center, Open Label Pilot Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum	Withdrawn	NCT00730717	Phase 2	Humira
20	Assessment of the Enrichment of Rare Coding Genetic Variants in Patients Affected by Neutrophil-Mediated Inflammatory Dermatoses	Unknown status	NCT01952275
21	Retrospective Multicenter Observational Study on the Clinical Features, Comorbidities and Pathologies Associated With Pyoderma Gangrenosum in Patients Diagnosed With This Pathology Between 2000 and 2015	Unknown status	NCT03636737
22	An Open Label Single Center Pilot Study Investigating the Clinical Response and Mechanism of Action of Infliximab in the Treatment of Adults With Inflammatory Bowel Disease Who Have Moderate to Severe Pyoderma Gangrenosum	Completed	NCT00791557		Infliximab
23	The Epidemiology of Group A Streptococcal Infections in Fiji (Fiji GrASP) - Part 4 -The Prevalence of Group A Streptococcal Pyoderma and Scabies in Infants in Fiji	Completed	NCT00436891
24	The Epidemiology of Group A Streptococcal Infections in Fiji (Fiji GrASP) Part 3: The Incidence of Group A Streptococcal Pharyngitis and the Prevalence of Pyoderma and Scabies in School Children in Fiji, and Establishing Immunologic Correlates of Protection for a J8 Vaccine	Completed	NCT00284882
25	The Epidemiology of Group A Streptococcal Infections in Fiji (Fiji GrASP) Part 1: The Prevalence of Rheumatic Heart Disease, Pyoderma and Scabies in School Children in Fiji	Completed	NCT00284843
26	East Arnhem Healthy Skin Project: A Regional Collaboration to Reduce Scabies, Skin Sores and Associated Chronic Diseases, Including Rheumatic Fever and Renal Disease, Among Australian Aboriginal Communities	Completed	NCT00884728
27	Post-marketing Observational Study for Humira in Participants Diagnosed With Pyoderma Gangrenosum (PG)	Recruiting	NCT04750213
28	A Real World, Observational Registry of Chronic Wounds and Ulcers to Assess Quality of Care, Evidence Based Practice and Outcomes Using Linked Electronic Health Record Data	Recruiting	NCT02280733
29	Phase 0/1 Topical Application of the Monoclonal Antibody (Mab) sB24M in Patients With Severe Pyoderma	Active, not recruiting	NCT04895566	Early Phase 1
30	Expression of the JAK-STAT Signaling Pathway in Pyoderma Gangrenosum Pathological Biopsy	Not yet recruiting	NCT04792957

Search NIH Clinical Center for Pyoderma

Cochrane evidence based reviews: pyoderma

Sources

Genetic Tests for Pyoderma

Sources

Anatomical Context for Pyoderma

Organs/tissues related to Pyoderma:

MalaCards : Skin, Neutrophil, Breast, Heart, Endothelial, Myeloid, Spleen

Sources

Publications for Pyoderma

Articles related to Pyoderma:

(show top 50) (show all 5198)

#	Title	Authors	PMID	Year
1	De novo mutation in the BTK gene of atypical X-linked agammaglobulinemia in a patient with recurrent pyoderma. ⁵³ ⁶²	Lin MT...Yang HC	16729790	2006
2	Neutrophilic dermatoses. ⁶²	Delaleu J...Bouaziz JD	35870984	2022
3	Cutaneous manifestations of antineutrophil cytoplasmic antibody-associated vasculitis (AAV): a concise review with emphasis on clinical and histopathologic correlation. ⁶²	Gibson LE	35599359	2022
4	Blastomycosis-like pyoderma: A pitfall for the misdiagnosis of squamous cell carcinoma. ⁶²	Ilagan FMD...Wu YH	35922899	2022
5	[Clinical analysis of 49 cases of non-inflammasome related conditions]. ⁶²	Zhang CH...Song HM	36444428	2022
6	Rituximab and Pyoderma Gangrenosum: An Investigation of Disproportionality Using a Systems Biology-Informed Approach in the FAERS Database. ⁶²	Hillen JB...Pratt N	35933497	2022
7	Pyoderma gangrenosum after mRNA-based SARS-CoV-2 vaccine. ⁶²	Franceschi J...Milpied B	35771124	2022
8	Successful treatment of pyoderma gangrenosum using adalimumab in a patient undergoing hemodialysis. ⁶²	Seishima M...Sugie S	35862244	2022
9	Improvement of refractory pyoderma gangrenosum with adjunctive maggot debridement therapy. ⁶²	Dozier L...Kerdel F	36468819	2022
10	Treatment of pyoderma gangrenosum with apremilast monotherapy. ⁶²	Bordeaux ZA...West CE	36345410	2022
11	Disseminated superficial granulomatous pyoderma. ⁶²	Gambichler T...Boms S	35560865	2022
12	A Case of Post-caesarean Pyoderma Gangrenosum. ⁶²	Bal H...Lal S	36457428	2022
13	Antibiotic-resistant status and pathogenic clonal complex of canine Streptococcus canis-associated deep pyoderma. ⁶²	Imanishi I...Hayashi S	36352470	2022
14	Pyoderma Gangrenosum Affecting the Dorsal Hand: A Case Report. ⁶²	Haase LR...Bafus BT	36337430	2022
15	A Rare Complication: Postoperative Pyoderma Gangrenosum in Segmental Colitis Associated With Diverticulosis. ⁶²	Dunleavy K...Pardi D	36001403	2022
16	Characterization of Legal Claims Involving Patients with Pyoderma Gangrenosum. ⁶²	Pfeifer HJ...Ortega Loayza AG	35895601	2022
17	Clinical characteristics and misdiagnosis of pyoderma gangrenosum of the head and neck: A retrospective study. ⁶²	Reese AM...Ortega-Loayza AG	35151756	2022
18	Pyoderma Gangrenosum after COVID-19 Infection and Vaccination. ⁶²	Zou H...Daveluy S	36442730	2022
19	Pyoderma Gangrenosum. ⁶²	Zhou HY...Liu ZH	36351270	2022
20	Peristomal granulation tissue mimicking peristomal pyoderma gangrenosum in the context of urine-diverting ostomies. ⁶²	McLarney BD...Hsu S	36186406	2022
21	[Development of spindle cell squamous cell carcinoma within a longstanding pyoderma gangrenosum]. ⁶²	Drexler K...Karrer S	35471236	2022
22	Clinical efficacy of flap transplantation combined with vacuum sealing drainage and methylprednisolone and cyclosporine in the treatment of pyoderma gangrenosum. ⁶²	Hao Y...Feng Z	36321334	2022
23	Pyoderma caused by Proteus mirabilis in sheep. ⁶²	Abdollahi M...Tamai IA	36049140	2022
24	Novel and Off-Label Biologic Use in the Management of Hidradenitis Suppurativa, Pyoderma Gangrenosum, Lichen Planus, and Seborrheic Dermatitis: A Narrative Review. ⁶²	Mital R...Kaffenberger BH	36434425	2022
25	Skin Infections Due to Panton-Valentine Leukocidin–Producing S. Aureus. ⁶²	Leistner R...Nurjadi D	36097397	2022
26	Canakinumab treatment in a young girl with refractory chronic recurrent multifocal osteomyelitis associated with pyoderma gangrenosum. ⁶²	Acierno S...Giani T	36004431	2022
27	Pyoderma Gangrenosum Triggered by COVID-19 Vaccination in a Patient with Ulcerative Colitis: A Case Report. ⁶²	Kim YC...Park YJ	36426538	2022
28	A case with prediagnosis of soft tissue infection who finally diagnosed as pyoderma gangrenosum of ulcerative colitis. ⁶²	Duzenli T	36412491	2022
29	Skin Manifestations in Patients with Selective Immunoglobulin E Deficiency. ⁶²	Picado C...Mascaro JM	36431272	2022
30	Case Report: Disseminated Vegetating Plaques Occurring over Chronic Recalcitrant Dermatophyosis in an Immunocompromised Patient. ⁶²	Chhabra N...George C A	36375465	2022
31	Synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome associated with pyoderma gangrenosum: report of two patients. ⁶²	Ma M...Li C	36345566	2022
32	Clinical characteristics of peristomal pyoderma gangrenosum: A Single Center Retrospective Observational Study. ⁶²	Honma M...Tani C	35789032	2022
33	Limb amputation in patients with pyoderma gangrenosum: a multi-institutional case series. ⁶²	Shakshouk H...Ortega-Loayza AG	36446938	2022
34	In Vitro Antimicrobial Activity of Piper betle Leaf Extract and Some Topical Agents against Methicillin-Resistant and Methicillin-Susceptible Staphylococcus Strains from Canine Pyoderma. ⁶²	Phensri P...Pruksakorn C	36428430	2022
35	Characterizing biofilm formation of Staphylococcus pseudintermedius in different suture materials. ⁶²	Pesset CM...Penna B	36155066	2022
36	Brocq's geometric phagedena over penis with keloidal scars. ⁶²	A S...Jayaraman J	36220799	2022
37	Prevalence of mecA, mecC and Panton-Valentine-Leukocidin Genes in Clinical Isolates of Coagulase Positive Staphylococci from Dermatological Canine Patients. ⁶²	Platenik MO...Santoro D	36422308	2022
38	Juvenile gangrenous vasculitis of the scrotum: systematic review. ⁶²	Bazzi N...Moussa M	35323998	2022
39	Multicenter Real-world Experience of Upadacitinib in the Treatment of Crohn's Disease. ⁶²	Chugh R...Kane SV	36272109	2022
40	Postherpetic Trigeminal Trophic Syndrome: A Case Report. ⁶²	Lee JH...Lee SK	36198630	2022
41	A Rare Form of Granulomatosis With Polyangiitis With Pyoderma Gangrenosum. ⁶²	Samardzic T...Felek S	36407211	2022
42	Antibiotic resistance profiles and activity of clove essential oil (Syzygium aromaticum) against Pseudomonas aeruginosa isolated of canine otitis. ⁶²	Costa LV...de Almeida ADBPF	36425137	2022
43	Abscess-like skin and lung lesions in a patient with acute lymphoblastic leukemia: Pyoderma gangrenosum. ⁶²	Akyol S...Oren H	35278042	2022
44	Pyoderma gangrenosum-like ulcers over the face in a case of granulomatosis with polyangiitis. ⁶²	Kanan K...Patra S	36250767	2022
45	Staphylococci isolated from cats in Italy with superficial pyoderma and allergic dermatitis: Characterisation of isolates and their resistance to antimicrobials. ⁶²	Cavana P...Nebbia P	36221849	2022
46	Trunk-dominant and classic facial pemphigus foliaceus in dogs - comparison of anti-desmocollin-1 and anti-desmoglein-1 autoantibodies and clinical presentations. ⁶²	Bizikova P...Mamo LB	35670648	2022
47	Off-label uses of ustekinumab. ⁶²	Ye L...Wang L	36208443	2022
48	Aseptic Abscess Syndrome With Ulcerative Colitis and Pyoderma Gangrenosum. ⁶²	Ozeki K...Kataoka H	35643412	2022
49	An unusual presentation of celiac disease in adult patient. ⁶²	Frioui R...Hammami H	36245465	2022
50	The "Understanding Pyoderma Gangrenosum, Review and Assessment of Disease Effects (UPGRADE)" Project: a protocol for the development of the core outcome domain set for trials in pyoderma gangrenosum. ⁶²	Rick J...Ortega-Loayza AG	36305958	2022

Sources

Genes for Pyoderma

Genes related to Pyoderma (0 elite genes):

(show all 30)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	PSTPIP1	Proline-Serine-Threonine Phosphatase Interacting Protein 1	Protein Coding	26.43	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Summaries (show sections)
2	MEFV	MEFV Innate Immunity Regulator, Pyrin	Protein Coding	23.52	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
3	TNF	Tumor Necrosis Factor	Protein Coding	14.71	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
4	NOD2	Nucleotide Binding Oligomerization Domain Containing 2	Protein Coding	13.93	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
5	CXCL8	C-X-C Motif Chemokine Ligand 8	Protein Coding	13.75	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
6	CSF3	Colony Stimulating Factor 3	Protein Coding	13.66	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
7	IL1R1	Interleukin 1 Receptor Type 1	Protein Coding	12.76	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
8	MMP9	Matrix Metallopeptidase 9	Protein Coding	12.09	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
9	PLCG2	Phospholipase C Gamma 2	Protein Coding	11.81	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
10	F3	Coagulation Factor III, Tissue Factor	Protein Coding	11.69	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
11	ITGB2	Integrin Subunit Beta 2	Protein Coding	11.62	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
12	IFNA2	Interferon Alpha 2	Protein Coding	11.1	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
13	APOH	Apolipoprotein H	Protein Coding	11.06	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
14	MMP1	Matrix Metallopeptidase 1	Protein Coding	10.85	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
15	MMP10	Matrix Metallopeptidase 10	Protein Coding	10.56	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
16	BTK	Bruton Tyrosine Kinase	Protein Coding	10.38	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	16729790
17	MMP26	Matrix Metallopeptidase 26	Protein Coding	10.09	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
18	MYOM2	Myomesin 2	Protein Coding	7.54	DISEASES inferred ¹⁴
19	CCR6	C-C Motif Chemokine Receptor 6	Protein Coding	7.53	DISEASES inferred ¹⁴ ¹⁴
20	C7	Complement C7	Protein Coding	7.28	GeneCards inferred via : Publications (show sections)
21	CHI3L1	Chitinase 3 Like 1	Protein Coding	7.28	GeneCards inferred via : Publications (show sections)
22	DSG1	Desmoglein 1	Protein Coding	7.12	DISEASES inferred ¹⁴
23	EDNRB	Endothelin Receptor Type B	Protein Coding	6.66	DISEASES inferred ¹⁴
24	IL1B	Interleukin 1 Beta	Protein Coding	6.65	DISEASES inferred ¹⁴
25	CRP	C-Reactive Protein	Protein Coding	6.64	DISEASES inferred ¹⁴
26	IL36RN	Interleukin 36 Receptor Antagonist	Protein Coding	6.64	DISEASES inferred ¹⁴
27	IL17A	Interleukin 17A	Protein Coding	6.52	DISEASES inferred ¹⁴
28	NLRP3	NLR Family Pyrin Domain Containing 3	Protein Coding	6.51	DISEASES inferred ¹⁴
29	MVK	Mevalonate Kinase	Protein Coding	6.45	DISEASES inferred ¹⁴
30	LPIN2	Lipin 2	Protein Coding	6.41	DISEASES inferred ¹⁴

Sources

Variations for Pyoderma

Sources

Expression for Pyoderma

Search GEO for disease gene expression data for Pyoderma.

Sources

Pathways for Pyoderma

Pathways related to Pyoderma according to GeneCards Suite gene sharing:

(show all 32)

#	Super pathways	Score	Top Affiliating Genes
1	MIF Mediated Glucocorticoid Regulation ⁶⁴ Show member pathways all-trans-Retinoic Acid Signaling in Brain ⁶⁴ Endothelin-1 Signaling Pathway ⁶⁴ Glucocorticoid Receptor Signaling ⁶⁴ IL-6 Pathway ⁶⁴ MIF Regulation of Innate Immune Cells ⁶⁴ NFAT Signaling and Lymphocyte Interactions ⁶⁴ Overview of proinflammatory and profibrotic mediators ⁷⁴ PEDF Induced Signaling ⁶⁴ PGC1Alpha Pathway ⁶⁴ RAR-Gamma-RXR-Alpha Degradation ⁶⁴ STAT3 Pathway ⁶⁴	13.56	BTK CCR6 CSF3 CXCL8 IFNA2 IL1R1
2	Akt Signaling ⁶⁴ Show member pathways p38 Signaling ⁶⁴ Tec Kinases Signaling ⁶⁴	13.34	TNF PLCG2 ITGB2 IL1R1 CXCL8 CSF3
3	Integrin Pathway ⁶⁴ Show member pathways FAK1 Signaling ⁶⁴ GnRH Signaling ⁶⁴ Inhibition of Angiogenesis by TSP1 ⁶⁴ Transendothelial Migration of Leukocytes ⁶⁴ UPA-UPAR Pathway ⁶⁴	13.31	PLCG2 MMP9 MMP26 MMP10 MMP1 ITGB2
4	PAK Pathway ⁶⁴ Show member pathways Antioxidant Action of Vitamin-C ⁶⁴ Epithelial Adherens Junctions ⁶⁴	13.23	TNF PLCG2 IL1R1 CXCL8 CSF3 CCR6
5	Innate Immune System ⁶⁶ Show member pathways Immune System ⁶⁶ Neutrophil degranulation ⁶⁶	13.05	TNF PSTPIP1 PLCG2 NOD2 MMP9 MMP1
6	Cytokine Signaling in Immune system ⁶⁶ Show member pathways Signaling by Interleukins ⁶⁶	13.04	TNF PLCG2 NOD2 MMP9 MMP1 ITGB2
7	Toll-like receptor signaling pathway ⁷⁴ Show member pathways Hepatitis B infection ⁷⁴ Measles virus infection ⁷⁴ Regulation of toll-like receptor signaling pathway ⁷⁴	12.76	BTK CXCL8 IFNA2 MMP9 TNF
8	IL-1 Family Signaling Pathways ⁶⁵ Show member pathways IL1 signaling pathway ⁶⁷ Immune response IL-1 signaling pathway ²² Interleukin-1 (IL-1) structural pathway ⁷⁴ Interleukin-33 signaling ⁶⁶ Interleukin-36 pathway ⁶⁶ Mucin expression in CF via TLRs, EGFR signaling pathways ²² Pathogen or Damage-activated C-Type Lectin Receptor Signaling Pathways ⁶⁵	12.53	TNF PLCG2 IL1R1 F3 CXCL8 BTK
9	Toll-Like receptor Signaling Pathways ⁶⁵ Show member pathways Inflammasome Activation Pathways ⁶⁵ Nanomaterial-induced inflammasome activation ⁷⁴ NOD-like Receptor Signaling Pathways ⁶⁵ TLR4 signaling and tolerance ⁷⁴ Toll-Like Receptors Pathway ⁶⁴	12.43	TNF NOD2 IL1R1 IFNA2 CXCL8
10	IL-17 Family Signaling Pathways ⁶⁵ Show member pathways IL17 signaling pathway ⁶⁷ IL-17 signaling pathway ⁷⁴ Mucin expression in CF via IL-6, IL-17 signaling pathways ²²	12.21	CSF3 CXCL8 MMP1 MMP9 TNF
11	Spinal cord injury ⁷⁴	11.93	TNF MMP9 IL1R1 CXCL8
12	Potential therapeutics for SARS ⁶⁶	11.83	PLCG2 IL1R1 BTK
13	CCL18 signaling pathway ⁷⁴	11.81	ITGB2 CXCL8 CCR6
14	Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways ⁶⁶ Show member pathways NOD1/2 Signaling Pathway ⁶⁶	11.8	PSTPIP1 NOD2 MEFV
15	Interleukin-4 and Interleukin-13 signaling ⁶⁶	11.8	TNF MMP9 MMP1 ITGB2 CXCL8
16	Allograft rejection ⁷⁴	11.79	TNF CXCL8 C7
17	Matrix metalloproteinases ⁷⁴ Show member pathways Activation of Matrix Metalloproteinases ⁶⁶ Inhibition of Matrix Metalloproteinases ⁶⁴	11.72	MMP1 MMP10 MMP26 MMP9 TNF
18	Innate Lymphoid Cells Differentiation ⁶⁵	11.71	TNF IL1R1 CCR6
19	AP-1 transcription factor network ⁶¹	11.64	MMP9 MMP1 CXCL8
20	Lung fibrosis ⁷⁴	11.58	CSF3 CXCL8 MMP9 TNF
21	Photodynamic therapy-induced NF-kB survival signaling ⁷⁴ Show member pathways Immune response MIF-mediated glucocorticoid regulation ²²	11.56	CXCL8 MMP1 MMP9 TNF
22	Cell adhesion_ECM remodeling ²²	11.52	MMP9 MMP10 MMP1 CXCL8
23	Burn wound healing ⁷⁴	11.43	TNF MMP9 MMP1 IFNA2 CXCL8
24	Bladder cancer ⁷⁴	11.38	MMP9 MMP1 CXCL8
25	Interleukin-10 signaling ⁶⁶	11.38	TNF IL1R1 CXCL8 CSF3
26	Validated transcriptional targets of AP1 family members Fra1 and Fra2 ⁶¹	11.3	MMP9 MMP1 CXCL8
27	Antiviral and anti-inflammatory effects of Nrf2 on SARS-CoV-2 pathway ⁷⁴	11.23	TNF MMP1 CXCL8
28	amb2 Integrin signaling ⁶¹	11.2	TNF MMP9 ITGB2
29	Prostaglandin signaling ⁷⁴	11.17	TNF MMP9 CXCL8
30	Non-genomic actions of 1,25 dihydroxyvitamin D3 ⁷⁴	11.06	TNF PLCG2 NOD2 IFNA2 CXCL8
31	G-protein signaling_Rap2B regulation pathway ²²	10.94	TNF ITGB2 CXCL8 CSF3 BTK
32	Cells and molecules involved in local acute inflammatory response ⁷⁴ Show member pathways IL8-mediated signaling events ⁶¹	10.31	TNF CXCL8

Sources

GO Terms for Pyoderma

Cellular components related to Pyoderma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	cell surface	GO:0009986	9.77	TNF NOD2 ITGB2 IL1R1 F3 CCR6
2	extracellular region	GO:0005576	9.68	TNF MMP9 MMP26 MMP10 MMP1 IL1R1

Biological processes related to Pyoderma according to GeneCards Suite gene sharing:

(show all 18)

#	Name	GO ID	Score	Top Affiliating Genes
1	immune response	GO:0006955	10.18	C7 CCR6 CSF3 CXCL8 IL1R1 TNF
2	extracellular matrix organization	GO:0030198	10.07	TNF MMP9 MMP26 MMP10 MMP1
3	positive regulation of phagocytosis	GO:0050766	10.03	TNF NOD2 BTK
4	positive regulation of interleukin-6 production	GO:0032755	10.03	TNF PLCG2 NOD2 BTK
5	extracellular matrix disassembly	GO:0022617	10.02	MMP9 MMP10 MMP1
6	inflammatory response	GO:0006954	10	CXCL8 IFNA2 IL1R1 ITGB2 MEFV PSTPIP1
7	response to lipopolysaccharide	GO:0032496	9.97	TNF PLCG2 NOD2 BTK
8	positive regulation of NF-kappaB transcription factor activity	GO:0051092	9.97	TNF PLCG2 NOD2 ITGB2 BTK
9	defense response	GO:0006952	9.89	TNF NOD2 IFNA2 CXCL8
10	positive regulation of I-kappaB phosphorylation	GO:1903721	9.88	TNF PLCG2
11	positive regulation of humoral immune response mediated by circulating immunoglobulin	GO:0002925	9.84	TNF NOD2
12	positive regulation of dendritic cell cytokine production	GO:0002732	9.81	PLCG2 NOD2
13	positive regulation of synoviocyte proliferation	GO:1901647	9.78	TNF BTK
14	positive regulation of prostaglandin-E synthase activity	GO:2000363	9.71	ITGB2 NOD2
15	leukocyte migration involved in inflammatory response	GO:0002523	9.65	TNF ITGB2 CCR6
16	collagen catabolic process	GO:0030574	9.56	MMP9 MMP26 MMP10 MMP1
17	cellular extravasation	GO:0045123	9.46	TNF ITGB2
18	calcium-mediated signaling	GO:0019722	9.32	TNF PLCG2 CXCL8 CCR6 BTK

Molecular functions related to Pyoderma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	metalloendopeptidase activity	GO:0004222	9.56	MMP9 MMP26 MMP10 MMP1
2	metallopeptidase activity	GO:0008237	9.02	MMP9 MMP26 MMP10 MMP1

Sources

Sources for Pyoderma

¹ BitterDB

² CDC

³ Cell Signaling Technology

⁴ ClinicalTrials

⁵ ClinVar

⁶ CNVD

⁷ Cochrane Library

⁸ Cosmic

⁹ dbSNP

¹⁰ DGIdb

¹¹ Disease Ontology

¹² diseasecard

¹³ DiseaseEnhancer

¹⁴ DISEASES

¹⁵ DrugBank

¹⁶ EFO

¹⁷ ExPASy

¹⁸ FMA

¹⁹ GARD

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ GenomeRNAi

²⁶ GEO DataSets

²⁷ GO

²⁸ GTR

²⁹ HMDB

³⁰ HPO

³¹ ICD10

³² ICD10 via Orphanet

³³ ICD11

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ LifeMap

³⁷ LncRNADisease

³⁸ LOVD

³⁹ MalaCards

⁴⁰ MedGen

⁴¹ MedlinePlus

⁴² MedlinePlus Genetics

⁴³ MeSH

⁴⁴ MESH via Orphanet

⁴⁵ MGI

⁴⁶ miR2Disease

⁴⁷ NCBI Bookshelf

⁴⁸ NCI

⁴⁹ NCIt

⁵⁰ NDF-RT

⁵¹ NIH Clinical Center

⁵² NINDS

⁵³ Novoseek

⁵⁴ Novus Biologicals

⁵⁵ ODiseA

⁵⁶ OMIM via Orphanet

⁵⁷ OMIM® (Updated 08-Dec-2022)

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubChem

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ WikiPathways

⁷⁵ Wikipedia

MCID: PYD002 MIFTS: 51	Pyoderma Categories: Skin diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables